|
LA JOLLA PHARMACEUTICAL TO PRESENT
AT BIO CEO & INVESTOR CONFERENCE
SAN DIEGO, February 19, 2002 -- La Jolla
Pharmaceutical Company (Nasdaq: LJPC)
announced today that Steven B. Engle,
Chairman and CEO, will present an update
on the Company's activities on Thursday,
February 21, at 1:40 PM eastern time
at the Biotechnology Industry Organization's
CEO & Investor Conference 2002 at
the Waldorf-Astoria Hotel in New York.
La Jolla Pharmaceutical Company is
a biotechnology company leading the
development of therapeutics for antibody-mediated
autoimmune diseases afflicting several
million people in the United States
and Europe. The Company is conducting
a Phase III trial of LJP 394 in patients
with lupus kidney disease, a leading
cause of sickness and death in these
patients. The Company is also conducting
a Phase I/II trial of LJP 1082 for the
treatment of antibody-mediated thrombosis,
a condition in which patients suffer
from recurrent stroke, deep-vein thrombosis
and other thrombotic events. The Company's
common stock is traded on The Nasdaq
Stock Market under the symbol LJPC.
For more information about the Company,
visit our Web site: http://www.ljpc.com.
Patients interested in the Phase III
lupus trial may call 1-888-30-LUPUS
for information.
Except for historical statements,
this press release contains forward-looking
statements, including, without limitation
statements regarding the analysis of
results from preclinical and clinical
studies as well as La Jolla Pharmaceutical's
drug candidates and drug development
plans. These forward-looking statements
involve risks and uncertainties, and
a number of factors, both foreseen and
unforeseen, could cause actual results
to differ materially from those anticipated.
Previously announced clinical results
for LJP 394 are derived from a trial
that was terminated prior to completion,
and certain data are incomplete. The
Company's blood test to measure binding
affinity for LJP 394 is experimental
and has not been validated by independent
laboratories. Tolerance, or the specific
inactivation of pathogenic B cells,
is a new technology that has not been
proven. The Company's ability to develop
and sell its products in the future
may be affected by the intellectual
property rights of third parties. Future
clinical trials of the Company's drug
candidates may have negative or inconclusive
results. Future clinical trials of the
Company's drug candidates may not support
results of preclinical or other prior
trials of LJP 394 for treating lupus
or LJP 1082 for treating antibody-mediated
thrombosis, and may reveal a potential
safety issue requiring the development
of new candidates. Any delays in testing
of the Company's drug candidates and/or
termination of development by the Company
would result in delays or lack of government
approval to market the compounds. The
development of drug candidates involves
many risks and uncertainties, including,
without limitation, whether the drug
can provide a meaningful clinical benefit,
and any positive results observed to
date may not be indicative of future
results. La Jolla Pharmaceutical's other
potential drug candidates involve comparable
risks. Interested parties are urged
to review the risks detailed from time
to time in La Jolla Pharmaceutical Company's
Securities and Exchange Commission (SEC)
filings, including the report on Form
10-K for the year ended December 31,
2000.
Terms
of Use & Privacy Policy
Copyright © 2008, La Jolla Pharmaceutical Company
|